Viatris Inc. (NASDAQ: VTRS) announced long-term financial targets through 2030 during an investor event, projecting sustained revenue and earnings growth based on its evolving portfolio and pipeline developments.

The pharmaceutical company outlined combined long-term targets of 5% to 6% total revenue compound annual growth rate, 7% to 8% adjusted EBITDA CAGR, 9% to 10% adjusted earnings per share CAGR, and more than $3 billion in annual free cash flow by 2030.

These combined targets comprise base case projections and potential additional drivers. The base case targets anticipate 3% to 4% total revenue CAGR, 4% to 5% adjusted EBITDA CAGR, 6% to 7% adjusted EPS CAGR, and more than $2.7 billion in annual free cash flow by 2030.

"With a growing base business, multiple anticipated near-term launches, a promising innovative pipeline and the financial flexibility to pursue disciplined accretive business development, we believe Viatris is well positioned to deliver sustained revenue and earnings growth through the end of the decade," said CEO Scott A. Smith.

Viatris expects near-term product launches including fast-acting meloxicam and low-dose estrogen weekly patch in the U.S., and pitolisant and Effexor for generalized anxiety disorder in Japan. The company also cited potential blockbuster candidates selatogrel and cenerimod as growth drivers.

The company completed an enterprise-wide strategic review identifying approximately $650 million in gross cost savings over three years, with up to $250 million expected to be reinvested. CFO Doretta Mistras said the company expects more than $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development activities.

The targets are based on company projections and assumptions that are subject to various risks and uncertainties, according to the press release statement.